AdvanceCT announced recently that five life sciences companies are expanding their operations in Connecticut, including Cellsbin, EpiTET Therapeutics, NanomediGene, Oxylus Energy, and Talam Biotech.
Cutting-edge VC-backed startup Cellsbin, an oncology detection medical device manufacturer founded by a team of industry veterans and renowned experts in the fields of photonics, molecular biology, and AI, signed a lease at BioLabs in New Haven. Located blocks away from Yale University, Cellsbin is expanding their groundbreaking R&D efforts, investing roughly $1 million and adding 5 members to their staff.
EpiTET Therapeutics, a Yale University spinout that combines AI-enabled patient selection with targeted therapeutics to treat endometriosis and overcome immunotherapy resistance to enable cancer cures by eliminating disease associated macrophages, set up their first office at District in New Haven. The company will grow by 10 jobs and invest $8 million in the state as it continues through its pre-clinical and fundraising process.
Biotechnology R&D company NanomediGene, who specializes in nanotechnology and targeted drug delivery systems of proteins, drug molecules, genes, and cellular-based therapies, committed to expanding into Connecticut after securing a partnership with Yale University. Joining as a member of Biolabs and moving into their space at the 101 College Street bioscience tower in New Haven, Nanomedigene will create 10 jobs for their Connecticut workforce and invest more than $3 million in their new lab space.
Yale University-spinout Oxylus Energy, a green energy company working towards net zero carbon emissions through the conversion of CO2 directly into carbon-neutral fuels and chemicals via highly efficient and scalable electrolyzer technology, secured a facility to expand their work in Branford. Leveraging investment from Connecticut Innovations’ Clean Tech Fund, Oxylus will be adding 6 jobs to its headcount and investing $4.5 million in the town.
Formerly based in Dublin, Ireland, Talam Biotech, an agricultural R&D company that reduces heavy metals in food crops using microbes, relocated their headquarters and R&D facility to BioCT Commons in Groton. Drawn by the possibility of partnerships within the biotech cluster in Connecticut, the strong backbone of research universities, and the availability of a highly skilled talent pool, Talam is committed to building out on their existing team and investing in their new R&D capabilities.
“The growth of the life sciences industry in Connecticut has shown no signs of slowing down,” said John Bourdeaux, President and CEO of AdvanceCT. “Companies want to be a part of our bioscience ecosystem to gain access to the wealth of partnership opportunities that our colleges and universities and anchor institutions, like Boehringer Ingelheim, Pfizer, and Mannkind, can provide.”
“Connecticut continues to be open for business in the life sciences sector,” added Tim Miller, Senior Director of Business Development, Life Sciences at AdvanceCT, “with more opportunities for funding, a higher availability of state-of-the-art lab space, and one of the most concentrated R&D workforces in the nation, all at a much more affordable price point than Boston, New York City, or California. With these factors in mind, it’s easy to see how a city like New Haven is included among the ten fastest growing metropolitan areas for life sciences talent in the country. As a national leader in National Institutes of Health funding, bioscience patents, and bioscience venture capital investments per capita, Connecticut and AdvanceCT remain ready to assist any life sciences company that is looking to accelerate their growth.”